At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Inflammation
Most Recent Events
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 22 Mar 2000 Profile reviewed but no significant changes made
- 12 Mar 1996 New profile